Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT04569942




Registration number
NCT04569942
Ethics application status
Date submitted
23/09/2020
Date registered
30/09/2020
Date last updated
26/10/2023

Titles & IDs
Public title
Australasian Resuscitation In Sepsis Evaluation: FLUid or Vasopressors In Emergency Department Sepsis
Scientific title
Australasian Resuscitation In Sepsis Evaluation: FLUid or Vasopressors In Emergency Department Sepsis
Secondary ID [1] 0 0
ANZIC-RC/SP002
Universal Trial Number (UTN)
Trial acronym
ARISE FLUIDS
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Shock, Septic 0 0
Condition category
Condition code
Infection 0 0 0 0
Studies of infection and infectious agents
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Vasopressor
Other interventions - Fluids

Active comparator: Vasopressor - a restricted fluids and early vasopressor strategy

Active comparator: Fluids - a larger intravenous (IV) fluid volume and later vasopressor strategy


Treatment: Drugs: Vasopressor
Cease IV fluid resuscitation. If persisting hypotension and/or hypoperfusion commence a vasopressor infusion (e.g. noradrenaline) and titrate according to local practice to achieve target MAP. The target MAP will be determined by the treating clinician. Reassess at least hourly for up to 6 hours post-randomisation, then as clinically required in conjunction with the protocol. Boluses of 250ml of IV fluids are permitted if deemed indicated by the treating clinician.

Other interventions: Fluids
An fluid bolus of up to 1000ml will be administered over a maximum of 1 hour, if required, for persisting hypotension and/or hypoperfusion. Reassess at least hourly to 6 hours post-randomisation, then as clinically required in conjunction with the protocol. Further IV fluid boluses of 500ml are recommended as clinically indicated to achieve the target MAP. The target MAP will be determined by the treating clinician. Haemodynamic resuscitation will be guided by usual clinical assessment including vital signs, mentation, perfusion, and urine output until the treating clinician determines fluid resuscitation is no longer clinically required. A minimum of 2-3 L (30 ml/kg), including pre-randomisation fluids, is recommended within 3 hours of ED arrival consistent with the SSC guidelines, unless clinically contraindicated. Vasopressors may be commenced if blood pressure remains below target despite optimal fluid resuscitation as determined by the treating clinician.
Intervention code [1] 0 0
Treatment: Drugs
Intervention code [2] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Days alive and out of hospital
Timepoint [1] 0 0
From randomisation until 90 days post- randomization
Secondary outcome [1] 0 0
Mortality
Timepoint [1] 0 0
From randomisation until 90 days post- randomization
Secondary outcome [2] 0 0
Time from randomization until death
Timepoint [2] 0 0
From randomisation until 90 days post- randomization
Secondary outcome [3] 0 0
Days alive and at home
Timepoint [3] 0 0
From randomisation until 90 days post- randomization
Secondary outcome [4] 0 0
Ventilator-free days to day 28
Timepoint [4] 0 0
From randomisation until 28 days post- randomization
Secondary outcome [5] 0 0
Vasopressor-free days to day 28
Timepoint [5] 0 0
From randomisation until 28 days post- randomization
Secondary outcome [6] 0 0
Renal replacement therapy-free days to day 28
Timepoint [6] 0 0
From randomisation until 28 days post- randomization
Secondary outcome [7] 0 0
Death or disability at 6 months
Timepoint [7] 0 0
at 6 months post randomization
Secondary outcome [8] 0 0
Death or disability at 12 months
Timepoint [8] 0 0
at 12 months post randomization

Eligibility
Key inclusion criteria
* Clinically suspected infection;
* Systolic blood pressure (SBP) <90 mm Hg or mean arterial pressure (MAP) <65 mm Hg, despite a ?1000ml cumulative total bolus of IV fluid administered over a maximum of 60 minutes; including pre-hospital boluses;
* Arterial or venous blood lactate >2.0 mmol/L;
* At least one dose of an intravenous antimicrobial has been commenced.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Age <18 years;
* Confirmed or suspected pregnancy;
* Transferred from another acute care facility;
* Hypotension suspected to be due to a non-sepsis cause;
* >2L total IV fluid administered (including prehospital fluids but excluding drugs and flushes);
* More than 6 hours has elapsed since presentation to the ED or more than 2 hours has elapsed since last inclusion criterion has been met;
* Treating clinician considers that one or both of the treatment regimens are not suitable for the patient or the study protocol cannot be delivered e.g. limitation of care, requirement for immediate surgery;
* Death is considered imminent or inevitable;
* Underlying disease that makes survival to 90 days unlikely;
* Inability to follow patient up to day-90 e.g. unstable accommodation, overseas visitor;
* Previously enrolled in this study.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
26/10/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
31/12/2025
Actual
Sample size
Target
1000
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC,WA
Recruitment hospital [1] 0 0
Bankstown Hospital - Bankstown
Recruitment hospital [2] 0 0
Royal Prince Alfred Hospital - Camperdown
Recruitment hospital [3] 0 0
John Hunter Hospital - New Lambton Heights
Recruitment hospital [4] 0 0
Royal North Shore Hosptial - Sydney
Recruitment hospital [5] 0 0
Mackay Base Hospital - Mackay
Recruitment hospital [6] 0 0
Robina Hospital - Robina
Recruitment hospital [7] 0 0
Gold Coast University Hospital - Southport
Recruitment hospital [8] 0 0
Toowoomba Hospital - Toowoomba
Recruitment hospital [9] 0 0
The Queen Elizabeth Hospital - Adelaide
Recruitment hospital [10] 0 0
Bendigo Hospital - Bendigo
Recruitment hospital [11] 0 0
Box Hill Hospital - Box Hill
Recruitment hospital [12] 0 0
Angliss Hospital - Ferntree Gully
Recruitment hospital [13] 0 0
Austin Health - Heidelberg
Recruitment hospital [14] 0 0
Alfred Hospital - Melbourne
Recruitment hospital [15] 0 0
Maroondah Hospital - Ringwood East
Recruitment hospital [16] 0 0
St John of God Murdoch Hospital - Murdoch
Recruitment hospital [17] 0 0
Royal Perth Hospital - Perth
Recruitment postcode(s) [1] 0 0
2200 - Bankstown
Recruitment postcode(s) [2] 0 0
2050 - Camperdown
Recruitment postcode(s) [3] 0 0
2305 - New Lambton Heights
Recruitment postcode(s) [4] 0 0
2065 - Sydney
Recruitment postcode(s) [5] 0 0
4740 - Mackay
Recruitment postcode(s) [6] 0 0
4226 - Robina
Recruitment postcode(s) [7] 0 0
4215 - Southport
Recruitment postcode(s) [8] 0 0
4350 - Toowoomba
Recruitment postcode(s) [9] 0 0
5011 - Adelaide
Recruitment postcode(s) [10] 0 0
3550 - Bendigo
Recruitment postcode(s) [11] 0 0
3128 - Box Hill
Recruitment postcode(s) [12] 0 0
3156 - Ferntree Gully
Recruitment postcode(s) [13] 0 0
3084 - Heidelberg
Recruitment postcode(s) [14] 0 0
3004 - Melbourne
Recruitment postcode(s) [15] 0 0
3135 - Ringwood East
Recruitment postcode(s) [16] 0 0
6150 - Murdoch
Recruitment postcode(s) [17] 0 0
6000 - Perth

Funding & Sponsors
Primary sponsor type
Other
Name
Australian and New Zealand Intensive Care Research Centre
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This multicentre, randomised controlled trial will enrol 1000 patients presenting with septic shock to the emergency department (ED) of participating hospitals in Australia and New Zealand. Participants will receive haemodynamic resuscitation with either a restricted fluids and early vasopressor regimen or a larger initial IV fluid volume with later introduction of vasopressors if required. Clinical care including the type of resuscitation fluid and vasopressor agent, will otherwise be in accordance with accepted standard care and according to clinician discretion. The study intervention will be delivered for at least 6 hours and up to 24 hours post-randomisation. Participants will be followed for up to 12 months and outcomes analysed on an intention-to-treat basis.
Trial website
https://clinicaltrials.gov/study/NCT04569942
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Sandra Peake, MBBS
Address 0 0
Monash University
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Belinda D Howe, MPH
Address 0 0
Country 0 0
Phone 0 0
0399030340
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT04569942